Fresh details have emerged surrounding Ghana’s decision to reject a proposed $109 million health assistance package from the administration of Donald Trump, with concerns reportedly centred on national sovereignty, data protection, legal control, and long-term policy implications.
At the heart of the proposal was the “America First Global Health Strategy,” a policy framework aimed at encouraging lower-income nations to gradually reduce dependence on foreign aid while taking greater responsibility for combating diseases such as HIV/AIDS, malaria, tuberculosis, and polio.
According to sources familiar with the negotiations, discussions began in November 2025 when the United States chargé d’affaires presented Ghana’s Ministry of Health Ghana with a Memorandum of Understanding (MoU) and requested that it be signed within one week.
Officials reportedly raised objections, arguing that the document had been drafted solely by the US side without Ghana’s input. Requests for a fresh, jointly negotiated agreement were said to have been declined, with pressure maintained for immediate endorsement.
Sources indicate that references were made to other countries already signing similar agreements, while Ghanaian officials were urged to move quickly. Despite this, authorities insisted on amendments and refused to proceed under the original terms.
One of the most contentious aspects of the proposal reportedly involved the treatment of citizens’ health data.
Under the agreement, Ghana would have been required to share health records with the United States for a period of 25 years, despite the aid programme itself being designed to run for only five years.
Officials who reviewed the document said the provisions granted broad discretion over how such data could be used, including possible access for American pharmaceutical firms for research, product development, and commercial activity.
This, according to insiders, triggered serious ethical, legal, and national security concerns.
Another major point of resistance related to Ghana’s medicine approval system.
The MoU allegedly contained provisions that would permit drugs approved by the U.S. Food and Drug Administration to enter Ghana’s market without undergoing the country’s standard regulatory approval process.
Such a move would significantly weaken the role of the Food and Drugs Authority Ghana, which is mandated under Ghanaian law to independently assess and certify medicines before local distribution.
Health officials reportedly viewed the clause as a threat to both regulatory autonomy and patient safety standards.
The agreement is also said to have stipulated that it would be governed under US law.
For Ghanaian authorities, this raised additional red flags, as any disputes arising from the arrangement could potentially be interpreted or resolved under a foreign legal framework rather than Ghana’s own legal system.
Beyond sovereignty concerns, the financial terms of the package also reportedly came under scrutiny.
While the US pledged $109 million over five years, Ghana was expected to provide $70 million in counterpart funding during the same period.
Sources say the American contribution was subject to congressional approval and funding availability, whereas Ghana’s obligation would have been binding. Failure by Ghana to meet its share could reportedly have triggered termination of the agreement.
Officials are said to have viewed the structure as uneven, with greater certainty and risk placed on Ghana’s side.
Following internal review, the Ministry of Health declined to proceed and referred the matter to Cabinet.
The Attorney-General’s Department Ghana reportedly advised against signing the agreement, after which Cabinet approved a full rejection of the package.
Ghana’s experience appears to reflect a broader trend.
Reports indicate that multiple countries engaged under the “America First Global Health Strategy” have begun raising concerns over terms attached to the agreements. Negotiations in Zimbabwe are said to have faced disruption, while agreements involving Kenya have reportedly drawn legal scrutiny from civil society groups.
Officials maintain that Ghana’s decision was not a rejection of support for critical health programmes, but a rejection of conditions deemed incompatible with national interests.
In balancing short-term financial gains against long-term implications for sovereignty, data privacy, and regulatory independence, authorities concluded that the risks outweighed the benefits.
